Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)5,8-Dichloro-7-(Methoxy(oxetan-3-Yl)methyl)-2-((4-Methoxy-6-Methyl-2-Oxo-1,2-Dihydropyridin-3-Yl)methyl)-3,4-Dihydroisoquinolin-1(2H)one (PF-06821497)

doi 10.1021/acs.jmedchem.7b01375.s001
Full Text
Abstract

Available in full text

Date

Unknown

Authors

Unknown

Publisher

American Chemical Society (ACS)


Related search